Ginkgo Bioworks Holdings (DNA) Income from Continuing Operations (2020 - 2026)
Ginkgo Bioworks Holdings posted quarterly Income from Continuing Operations of 76059000.0 for Q1 2026, up 8.7% year-on-year from 69969140.03 in Q1 2025, and up 5.81% on a QoQ basis from 80751000.0 in Q4 2025.
Ginkgo Bioworks Holdings (DNA) has 7 years of Income from Continuing Operations data on file, last reported at 76059000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 8.7% year-over-year to 76059000.0; the trailing twelve-month figure through Mar 2026 stood at 297865000.0 (up 35.86% YoY), and the FY2025 full-year result was 312763000.0, up 42.83% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 76059000.0, up from 80751000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 56403000.0 in Q3 2024 and bottomed at 670570000.0 in Q2 2022.
- The 5-year median for Income from Continuing Operations is 173078000.0 (2022), against an average of 231026176.47.
- Peak annual rise in Income from Continuing Operations reached 89.22% in 2022, while the deepest fall reached 1131.22% in 2022.
- A 5-year view of Income from Continuing Operations shows it stood at 173078000.0 in 2022, then retreated by 22.31% to 211694000.0 in 2023, then soared by 49.2% to 107534000.0 in 2024, then advanced by 24.91% to 80751000.0 in 2025, then grew by 5.81% to 76059000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 76059000.0 (Q1 2026), 80751000.0 (Q4 2025), and 80755000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Ginkgo Bioworks Holdings | 542.03 Mn | 542.03 Mn | 16.38 Mn | -76.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -76.06 Mn |
| Dec 31, 2025 | -80.75 Mn |
| Sep 30, 2025 | -80.76 Mn |
| Jun 30, 2025 | -60.30 Mn |
| Mar 31, 2025 | -83.31 Mn |
| Dec 31, 2024 | -107.53 Mn |
| Sep 30, 2024 | -56.40 Mn |
| Jun 30, 2024 | -217.18 Mn |
| Mar 31, 2024 | -165.91 Mn |
| Dec 31, 2023 | -211.69 Mn |
| Sep 30, 2023 | -302.89 Mn |
| Jun 30, 2023 | -173.32 Mn |
| Mar 31, 2023 | -204.97 Mn |
| Dec 31, 2022 | -173.08 Mn |
| Sep 30, 2022 | -670.13 Mn |
| Jun 30, 2022 | -670.57 Mn |
| Mar 31, 2022 | -592.59 Mn |
| Dec 31, 2021 | -1.60 Bn |
| Sep 30, 2021 | -102.41 Mn |
| Jun 30, 2021 | -54.46 Mn |
| Mar 31, 2021 | -74.78 Mn |
| Dec 31, 2020 | -46.40 Mn |
| Sep 30, 2020 | -26.13 Mn |